Adenosine A 2A receptors (A 2A Rs) are well positioned to influence the maladaptive CNS responses to repeated dopaminergic stimulation in psychostimulant addiction. Expression of A 2A Rs in brain is largely restricted to the nucleus accumbens and striatum, where molecular adaptations mediate chronic effects of psychostimulants such as behavioral sensitization. Using a novel forebrain-specific conditional (Cre/loxP system) knockout of the A 2A R in coordination with classical pharmacological approaches, we investigated the involvement of brain A 2A Rs in amphetamine-induced behavioral sensitization. Tissue-specific, functional disruption of the receptor was confirmed by autoradiography, PCR, and the loss of A 2A antagonist-induced motor stimulation. Daily treatment with amphetamine for 1 week markedly enhanced locomotor responses on day 8 in control mice and the sensitization remained robust after a week of washout. Their conditional knockout littermates however showed no sensitization to amphetamine on day 8 and only a modest sensitization following the washout. Pharmacological blockade of adenosine A 2A Rs also was able to block the development (but not the expression) of sensitization in multiple mouse strains. Thus activation of brain A 2A Rs plays a critical role in developing augmented psychomotor responses to repeated psychostimulant exposure.
INTRODUCTION
The behavioral effects of psychostimulants such as amphetamine and cocaine are mediated by their indirect activation of dopamine receptors in the nucleus accumbens and caudate-putamen (Koob, 1996) . Psychostimulants are thought to be addictive due to neuronal and molecular adaptations both within and outside the mesoaccumbens circuitry (Vanderschuren and Kalivas 2000) . Behavioral sensitization, which is described as a progressive augmentation of responses to repeated drug administration, is an expression of neuroadaptations. In humans, sensitization to psychostimulant drugs may appear as craving behavior or paranoia (Robinson and Berridge 1993; Kalivas et al, 1998) . Critical roles have been established for dopaminergic and subsequently glutamatergic transmission in psychostimulant-induced behavioral sensitization (Wolf, 1998) . Recently, the adenosine A 2A receptor (A 2A R) has also emerged as a potential modulator of psychostimulant sensitization and as an attractive therapeutic target. A 2A Rs are ideally located to modulate neuronal pathways involved in psychostimulant sensitization, given that their brain expression is largely restricted to the nucleus accumbens, striatum, and olfactory tubercle (Rosin et al, 2003) . Furthermore, A 2A adenosinergic and D 2 dopaminergic systems interact at the membrane (Ferre et al, 1994; Canals et al, 2003) , intracellular (Morelli et al, 1995) , and behavioral levels (Ferre et al, 1993; Fenu et al, 1997) . In addition, activation of A 2A Rs enhances the release of several brain neurotransmitters including dopamine and glutamate, which contribute to the development of psychostimulant behavioral sensitization (Quarta et al, 2004) .
Recent pharmacological data provide direct evidence for an important role of adenosine A 2A Rs in the long-term adaptive responses to repeated dopaminergic stimulation both in rats (Bove et al, 2002; Bibbiani et al, 2003) and nonhuman primates . In addition, using A 2A R knockout (A 2A KO) mice, our laboratory has shown that behavioral sensitization to repeated treatment either with L-dopa in hemiparkinsonian mice or with amphetamine in unlesioned mice does not develop in the absence of the A 2A R (Fredduzzi et al, 2002; Chen et al, 2003) . However, a facilitative role of A 2A Rs in sensitization is controversial and other reports have shown that the A 2A agonist CGS21680 attenuates the development of behavioral sensitization induced by methamphetamine (Shimazoe et al, 2000) . This discrepancy between genetic and pharmacological studies of A 2A Rs functions may reflect particular limitations of either of these approaches, for example, developmental or chronic inactivation of the A 2A R in the KO model, or exogenous vs endogenous modulation of the adenosinergic system using a pharmacological agonist.
In order to clarify the role for A 2A Rs in behavioral adaptations induced by repeated psychostimulant exposure, we used a brain-specific conditional KO of the A 2A R in coordination with a classical pharmacological approach. The genetic model allows us to specifically explore the A 2A R in forebrain areas and to avoid possible compensatory developmental responses of other genes, given the fact that the deletion of the A 2A R is postnatal. Moreover, we took advantage of newly available A 2A antagonists, which offer improved specificity despite persistent problems of solubility and stability, to test the role of the A 2A R in the development of amphetamine sensitization and its discrete phases (induction and expression).
MATERIALS AND METHODS

Generation and Genotyping of Postnatal
The L7ag13 line of CaMKIIa-cre transgenic mice (in a C57Bl/6 background) expresses the Cre recombinase under the direction of the CaMKIIa gene promoter in postnatal neurons of the striatum as well as other forebrain structures and in germline cells Morozov et al, 2003) and was kindly provided by WT Dauer, A Morozov, R Hen, and ER Kandel. Mice with a 'floxed' adenosine A 2A R gene were generated by insertion of loxP sequences within the introns flanking a critical exon Zakharenko et al, 2003) . This newly identified CaMKIIa promoter-driven recombination in female as well as male gametes may reflect differences in Cre-mediated recombination in germline cells seen with different floxed genesF presumably due to differences in local chromatin structure effects on loxP site accessibility (Morozov et al, 2003 flox/À (half that were cre( þ ) and half that were cre(À)) employed in this study of amphetamine sensitization (Figure 2) .
Genotyping for the presence of the cre transgene and separately for the presence of the wild-type (WT), floxed, or recombined (inactivated) alleles of the A 2A R gene was conducted by polymerase chain reaction (PCR) analysis of tail DNA unless otherwise indicated. The three-probe PCR strategy employed for A 2A genotyping is schematized in Figure 1b , and is based on the location of loxP inserts within the gene (Day and Linden, unpublished results).
Animals and Drug Treatments
All experiments were performed in accordance with the Massachusetts General Hospital and NIH guidelines on the ethical use of animals. Both colony and commercial (129-Steel and C57Bl/6) mice (Charles River Laboratories) were habituated to the testing environment for 120 min prior to behavioral testing. In the dose-response studies (Figure 3a ), mice were treated intraperitoneally (i.p.) with the A 2A antagonist SCH58261, KW-6002, or vehicle (10% DMSO, 15% ethoxylated castor oil, 75% distilled water). In the amphetamine-induced sensitization studies (Figure 3b-d) , as schematized in Figure 4 , mice received daily injections (in their test cage) of amphetamine (2.5 mg/kg, i.p.) combined with vehicle, SCH58261 (0.03 mg/kg, i.p.), or KW-6002 (0.03 mg/kg, i.p.) for 8 consecutive days. A 2A antagonists were injected 1-2 min before amphetamine. Locomotor activity was recorded (using an automated open field system) for 120 min following drug injection on days 1 and 8 and 1 and 2 weeks after the cessation of the treatment (days 15 and 22). In the induction study of amphetamine sensitization (Figure 5a ), drug treatments are identical to those of the amphetamine sensitization studies up to day 15. On day 22, the locomotor activity was monitored upon challenge with amphetamine (2.5 mg/kg, i.p.) alone in all mice. In the expression study (Figure 5b ), all mice were treated for 8 consecutive days with amphetamine alone (2.5 mg/kg, i.p.). A week after the last treatment (day 15), mice were treated either with amphetamine (2.5 mg/kg, i.p.) alone or paired with SCH58261 (0.03 mg/kg, i.p.), and their locomotor activity was recorded on days 1, 8, and 15. When using the A 2A conditional KO mice in the amphetamine sensitization study (Figure 2 ), animals were treated with amphetamine (2.5 mg/kg, i.p.) alone.
Locomotor and Fine Motor Activity
Horizontal locomotor and fine motor activity were primarily assessed by an automated recording system (San Diego Instruments) in standard polypropylene cages (15 Â 25 cm) (Figure 1c ), a manual blinded recording method for locomotor activity (time spent in horizontal motion during each 10 min period) was used.
Receptor Autoradiography
Qualitative receptor autoradiography for detecting A 2A Rs using the specific ligand Boston, MA) was performed as described previously (Chen et al, 1999) . Coronal brain and tissue sections were preincubated at room temperature with 50 mM Tris-HCl buffer, pH 7.5, and 1 U of adenosine deaminase for 30 min and then incubated with the Tris buffer containing 5 nM 3 H-CGS21680 for 60 min. To define nonspecific binding, 2.5 mM of 2-chloroadenosine was coincubated in adjacent sections.
Statistical Analysis
All data are expressed as mean7SEM. Statistical analyses were performed using Prism3 software. The effects of genotype and chronic treatment (treatment days 1, 8, and 15) were analyzed by two-way ANOVA followed by post-test using the Bonferroni method. For all the other behavioral studies, one-way ANOVA followed by Dunnett's test was applied.
RESULTS
Complete, Specific Inactivation of Adult Brain A 2A Rs in Conditional A 2A KO Mice
To clarify the neurobiology of A 2A Rs, we generated conditional A 2A KO mice using a forebrain-specific Cre/ loxP system (Morozov et al, 2003) . Transgenic mice expressing the Cre recombinase under the direction of the CaMKIIa gene promoter in postnatal forebrain neurons (including those of the striatum) were crossed with mice whose A 2A R gene contained loxP excision sequences inserted on either side of (ie flanking) a critical exon, yielding so-called 'floxed' A 2A R alleles. Successful forebrainspecific recombination was confirmed by autoradiographic, genetic, and behavioral assessments. . Together with genetic evidence against Cre-mediated recombination in all other peripheral somatic tissues tested (heart, spleen, tail; Figure 1b and data not shown) in CaMKIIa-cre( þ ) mice, these anatomical findings demonstrate the brain specificity of this conditional A 2A KO approach. It should be noted however that disruption of the A 2A R gene also occurred in some gonadal cells (due to variable germline expression of cre as expected with the CaMKIIa promoter; Morozov et al, 2003) , complicating breeding strategies to generate cre( þ ) A 2A flox/flox mice (see Materials and methods). In addition, within the CNS, the predicted further restriction of A 2A R gene recombination to the forebrain was confirmed by the genetic (PCR) analysis, showing prominent recombination of the floxed A 2A R allele in the frontal cortex and striatum but no detectable recombination in the cerebellum (as well as peripheral tissues) (Figure 1b) . Note that the relatively small amount of residual floxed (nonrecombined) A 2A R allele likely reflects the lack of cre expression in glial cells, since forebrain neurons rather than glia are primarily targeted in the CaMKIIa-cre( þ ) mice used here Morozov et al, 2003) . On the other hand, incomplete recombination in striatal neurons could be excluded as a contributor to the residual floxed A 2A R gene in the adult striatum.
In initially assessing the functional effects of eliminating A 2A Rs in adult striatal neurons, we examined behavioral flox/À (control) littermates. Although forebrain-specific A 2A R depletion had no effect on the locomotor response to a novel environment or to a habituating saline injection on day 0 (Figure 2a) , locomotor activity after the first dose of amphetamine was slightly greater in control mice (on day 1; Figure 2b and e). This is consistent with a partial A 2A R dependence of the acute stimulant action of amphetamine, which we had observed with a global A 2A R KO line (Chen et al, 2000) . Continued daily treatment with amphetamine markedly enhanced (sensitized) locomotor responses in control mice (po0.05 day 8 vs 1), whereas no sensitization to amphetamine occurred in their conditional KO littermates on day 8 (Figure 2c and e) . Similarly, 1 week after discontinuation of daily amphetamine exposure (day 15), robust locomotor sensitization persisted in control (po0.001 vs day 1) but was not seen in conditional A 2A KO mice (Figure 2d and e), although at this point a slightly enhanced locomotor activity appeared to be present in the conditional KO group compared to day 1 (po0.05) (Figure 2e ). Given this result and the fact that on day 1 the amphetamine response in the conditional A 2A KO was lower compared to the WT mice, we cannot exclude the possibility that the absence of sensitization on day 8 in the conditional A 2A KO is a reflection of subthreshold motor responses at the dose of amphetamine used in this study. We have however noted that the absence of sensitization we observed in global A 2A KO mice was independent of the amphetamine dose used and was not attributable to a threshold effect on sensitization.
The possibility that the absence of sensitization in conditional A 2A KO mice is due to the expression of the cre gene rather than the selective deletion of the A 2A R was excluded by the finding that (L7ag13) Brain A 2A receptors in sensitization E Bastia et al showed the same level of amphetamine sensitization as their nontransgenic (ie cre(À), fully WT) littermates (ambulations for 120 min after the eighth amphetamine dose: 41547844 and 35687854, respectively). Since amphetamine is known to induce stereotyped stationary behaviors as well as locomotion, we considered the possibility that the lack of locomotor sensitization in conditional KO mice could be due to immobility associated with increased stereotypes in these mice. However, an enhancement of amphetamine-induced fine movement behavior in the control mice on days 8 and 15 (po0.05) was also blocked in their A 2A conditional KO littermatesFwith increases from day 1 (182740 repetitive single photobeam breaks) to day 8 (391786) to day 15 (4567101) 
A 2A Antagonists Attenuate Amphetamine-Induced Locomotor Sensitization
To investigate whether pharmacological blockade of A 2A Rs can also attenuate amphetamine sensitization, we first determined the dose of A 2A antagonist to be paired with amphetamine administration. To avoid the confound of the motor stimulant effects of adenosine A 2A antagonists (Popoli et al, 1998; El Yacoubi et al, 2000; Halldner et al, 2000) , and given the evidence that doses of an A 2A antagonist below its threshold for motor stimulation are capable of modulating striatal physiology (Monopoli et al, 1998; Popoli et al, 2002) , we tested several doses of two different A 2A antagonists, SCH58261 and KW-6002. Both .01 vs amphetamine treatment at the same day. (b) C57Bl/6 mice (n ¼ 8) were treated with amphetamine (2.5 mg/kg) daily for 8 days. On day 15, mice were challenged with amphetamine paired to SCH58261 (0.03 mg/kg) or vehicle. *po0.05, ***po0.001 vs amphetamine at day 1. Note that although several fold variability in acute motor response to amphetamine is routinely observed between experiments (eg a vs b for day 1), the amphetamine-induced sensitization phenomenon occurs consistently. dose-dependently stimulated locomotor activity, with 0.3 mg/kg being the lowest dose that stimulated locomotion (Figure 3a) . Accordingly, we selected 0.03 mg/kg as a subthreshold dose (ie that does not enhance locomotor activity) for each antagonist to be coadministered with amphetamine in sensitization experiments. Pairing daily amphetamine doses with an A 2A antagonist (SCH58261 or KW-6002) prevented locomotor sensitization on day 8 in both 129-Steel and C57Bl/6 strains of mice (po0.05) (Figure 3b-d) . Upon rechallenge with amphetamine plus SCH58261 on days 15 and 22, C57Bl/6 mice still did not show sensitization, while sensitization remained undiminished in the amphetamine plus vehicle group (Figure 3d) . In contrast, 129-Steel mice developed a sensitized response upon delayed rechallenge with amphetamine plus SCH58261 on days 15 and 22 (Figure 3b) . Fine movements were also monitored and they paralleled the results with locomotor activity (data not shown). These data suggest that A 2A R blockade prevents or delays the development of locomotor sensitization to amphetamine, and that A 2A Rs facilitate neuroadaptive changes induced by repeated dopaminergic stimulation.
A 2A Rs are Required for the Induction (but not Expression) of Amphetamine Sensitization
We also explored the effects of adenosine A 2A Rs on discrete phases of sensitization. In particular, we challenged with amphetamine alone mice that have been daily treated with amphetamine or amphetamine plus the A 2A antagonist SCH58261 (0.03 mg/kg). Upon amphetamine challenge, locomotor activity of amphetamine plus SCH58261 chronically treated mice was still not sensitized and remained significantly lower than that of the amphetamine chronically treated mice (po0.05) (Figure 5a) . We also addressed possible A 2A R involvement in the expression phase of amphetamine sensitization. After having induced sensitization with daily administration of amphetamine alone, mice were challenged either with amphetamine or amphetamine paired with SCH58261 (0.03 mg/kg). Amphetamine-treated mice as well as SCH58261-treated mice still showed sensitization (po0.001 vs amphetamine day 1) (Figure 5b ). The data suggest that A 2A Rs play a role in the induction or maintenance of amphetamine-induced sensitization rather than its expression.
DISCUSSION
We have shown that postnatal inactivation of brain adenosine A 2A Rs dramatically attenuates sensitized behavioral responses to repeated amphetamine administration using a conditional gene depletion technique in combination with classical pharmacology. We previously showed that a global KO of the A 2A R (ie in all cells and at all times from conception onward) prevents amphetamine sensitization. However, our earlier study could not distinguish between a developmental, chronic, or acute inactivation of the A 2A R as the basis for this phenotype. Given that the A 2A R is expressed in brain as early as E-15 in rats (Weaver, 1993) , it was possible that altered development of dopaminergic, glutamatergic, GABAergic, or other CNS signaling systems in A 2A KO mice could lead to an alteration in their amphetamine-induced behavioral sensitization. Similarly, the global KO study could not distinguish between the effects of A 2A R inactivation in brain and its many effects in the periphery. The absence of amphetamine sensitization in the conditional KO in the present study argues strongly against compensatory developmental modifications by A 2A R depletion as the cause of altered amphetamineinduced sensitization because the particular (L7ag13) line of CaMKIIa-cre mice used here has been shown to reduce forebrain 'floxed' gene expression somewhere between postnatal days 6 and 60 . In addition, the conditional KO phenotype also largely excludes the possibility of non-CNS (or non-neuronal) A 2A Rs contributing to amphetamine sensitization, as we ( Figure 1 ) and others have found no evidence of Cre recombinase activity outside the brain (or neurons) in male CaMKIIa-cre mice except for that in testes, which is unlikely to be a major contributor to psychostimulant-induced sensitization.
Although the postnatal conditional KO strategy helps eliminate a role for developmental actions of A 2A Rs, the absence of forebrain A 2A Rs for weeks to months prior to repeated amphetamine administration in the cre( þ ), floxed A 2A mice precludes a distinction between effects of chronic receptor depletion and the effects of acute inactivation just at the times of the amphetamine exposure. To address A 2A R involvement in amphetamine sensitization with an even greater temporal resolution than afforded by the conditional KO, we turned to complementary pharmacological antagonists of the A 2A R that were administered acutely together with the individual amphetamine doses. Pairing of A 2A antagonists with amphetamine also prevented locomotor sensitization after eight daily drug injections in both the 129-Steel and C57Bl/6 mouse strains, but prevented persistent sensitization weeks later only in C57Bl/6 mice. The different durations of sensitization blockade in the two mouse strains might be related to their differences in the metabolism of the drugs as well as to different drug sensitivities in the CNS. It also might be possible that the phases of sensitization (eg induction and maintenance) are affected differently in different mouse strains. In any event, the recapitulation of the global and conditional A 2A KO phenotype of attenuated amphetamine sensitization in the antagonist-treated mice strengthens further the evidence against developmental or prolonged actions of the A 2A R as the basis for its facilitative role in psychostimulant sensitization. Thus, from the present findings, we can now conclude that postnatal forebrain A 2A RsFprobably on neuronsFplay a critical role in behavioral sensitization to repeated amphetamine administration.
The absence of behavioral sensitization to repeated amphetamine treatment in A 2A KO and antagonist-treated mice may reflect a broader phenotype of attenuated adaptive motor responses to intermittent dopaminergic stimulation. Fredduzzi et al (2002) showed that in unilaterally 6-OHDA-lesioned (global) A 2A KO mice, daily treatment with L-dopa did not produce progressively sensitized behaviors (contralateral rotations and grooming) compared to their WT littermates. In analogous pharmacological studies of A 2A R involvement in neuroplasticity induced by L-dopa in hemiparkinsonian rodents, Bibbiani et al (2003) have recently shown that oral KW-6002 coadministered with L-dopa daily prevented the characteristic shortening of motor response to acute L-dopa challenge. Together, these studies raise the possibility that the maladaptive involuntary movements (known as dyskinesias) that develop after chronic L-dopa treatment in Parkinson's disease may be reduced or prevented by antagonist coadministration. This hypothesis was strongly supported by a study of parkinsonian non-human primates in which chronic oral administration of KW-6002 with a dopaminergic agonist completely prevented the delayed development of dyskinesias . Furthermore, A 2A R involvement in neural adaptations may extend beyond those induced by direct dopaminergic stimulation. For example, El Yacoubi et al (2001) recently reported that classical genetic deletion of A 2A Rs also attenuates a withdrawal syndrome after chronic alcohol administration.
On the other hand, not all pharmacological studies have supported a facilitative role for A 2A Rs in the neural adaptations that underlie sensitization. Shimazoe et al (2000) found that the A 2A agonist CGS21680 attenuates sensitization to repeated methamphetamine administration in rats. Their use of a different psychostimulant drug and paradigm of sensitization, as well as an A 2A agonist (which may be less relevant to endogenous adenosine actions on CNS A 2A Rs than are A 2A antagonists) could account for the difference in results. Moreover, although Lundblad et al (2003) have confirmed that treatment of 6-OHDA-lesioned rats with an adenosine A 2A antagonist alone did not elicit any abnormal involuntary movements while relieving motor disabilities, they did not observe any effect of KW-6002 on the severity of dyskinesias when it was coadministered with L-dopa. Another study of unilaterally 6-OHDA-lesioned rats found that an A 2A antagonist reversed but did not prevent L-dopa-induced motor alterations (Bove et al, 2002) . In general, all these studies have suggested an A 2A R role in behavioral sensitization despite some differences in the nature of its role. The present study greatly strengthens the evidence that in the case of the brain A 2A R, its role in psychostimulant sensitization is facilitative.
Our finding that pharmacological blockade of A 2A Rs can be as effective as their genetic depletion in preventing amphetamine sensitization adds to the therapeutic potential of A 2A antagonists for neuropsychiatric diseases. Several A 2A antagonists (eg KW-6002) are already in various phases of clinical trials as a novel symptomatic treatment for Parkinson's disease. Our findings support the possibility that brain A 2A blockade may help prevent or delay the development of maladaptive dyskinetic motor responses to chronic dopaminergic stimulation (Pinna et al, 2001; Fredduzzi et al, 2002; Bibbiani et al, 2003) . Moreover, our data raise the possibility that A 2A antagonists could provide a rational pharmacological intervention for the treatment of addictive disorders. In support of A 2A antagonists as therapy in neuropsychiatric disorders is the efficacy of very low doses, which are subthreshold for stimulatory motor effects. The development of sensitization may result from a series of transient neural adaptations that occur with each drug administration, ultimately establishing enduring changes in the response of the brain to subsequent drug administration. Our results implicating CNS A 2A Rs in the development rather than the expression of amphetamine sensitization indicate not only that CNS A 2A Rs play a critical role in sensitized psychostimulant responses, but also that they could be targeted to prevent or delay the maladaptive neuroplasticity that contributes to the induction or maintenance phases of some addictive behaviors.
The neurochemical mechanisms by which basal ganglia A 2A Rs may facilitate behavioral sensitization are unknown. A 2A R inactivation may prevent behavioral sensitization by modulating presynaptic dopamine release (Zetterstrom and Fillenz 1990; Okada et al, 1996; Dassesse et al, 2001 ). Since there is no evidence of A 2A Rs expression on nigrostriatal neurons (Rosin et al, 2003) , it has been suggested that A 2A R-mediated facilitation of dopamine release may arise indirectly, that is, through regulation of glutamate and GABA release (Sebastiao and Ribeiro, 1996; Wolf, 1998; Corsi et al, 1999) . Alternatively, a direct postsynaptic interaction between A 2A and dopamine D 2 receptor may facilitate amphetamine sensitization. In addition, the interaction among A 2A and mGluR5 metabotropic glutamate receptors in the basal ganglia could also modulate psychostimulant-induced sensitization (Chiamulera et al, 2001) . Changes in the expression of presumably postsynaptic A 2A Rs after repeated dopaminergic exposures might also play a functional role in the nucleus accumbens or dorsal striatum (Zeng et al, 2000; Calon et al, 2004; Tomiyama et al, 2004) . Potential downstream postsynaptic mediators of sensitization that are also known to be regulated by the A 2A R include cytoplasmic signal transducers (eg dopamineand cAMP-regulated phosphoprotein of 32 kDa or DARPP-32) and nuclear transcriptional targets (eg DFosB, enkephalin, and dynorphin gene expression in striatal neurons; Fienberg et al, 1998; Canals et al, 2003; Lundblad et al, 2003; Hakansson et al, 2004) .
In summary, by complementing classical pharmacology with a powerful new conditional KO approach to brain receptor inactivation, we have demonstrated that antagonists of the A 2A R and its genetic disruption in the postnatal forebrain markedly attenuate behavioral sensitization to repeated amphetamine exposure. Furthermore, the findings indicate a critical if not requisite role for brain A 2A Rs in an early phase of psychostimulant-induced neuroplasticity. Thus, targeting the A 2A R in the basal ganglia may provide a novel therapeutic strategy to prevent or reduce maladaptive biochemical and behavioral responses to repeated drug administration in human psychostimulant addiction.
